MSI in Circulatory DNA of Endometrial Cancer

Status Recruiting

Clinical Trial Summary

This study aims to analyze the microsatellite instability (MSI) in the circulatory tumor DNA and in the tumor tissue in the patients diagnosed with uterine endometrial cancer. These data will be used for the study of "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer" (NCT03291106, clinicaltrials.gov).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Circulating Tumor Cell
Colorectal Neoplasms, Hereditary Nonpolyposis
Endometrial Cancer
Endometrial Neoplasms
Lynch Syndrome
Microsatellite Instability
Neoplastic Cells, Circulating

Clinical Trial Details

NCT number	NCT03744962
Study type	Observational
Source	Peking Union Medical College Hospital
Contact	Lei Li, M.D.
Phone	13911988831
Email	lileigh@163.com
Status	Recruiting
Phase
Start date	November 10, 2018
Completion date	December 23, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05796518` - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors	N/A
Recruiting	`NCT05489211` - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT06463028` - Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer	Phase 2
Recruiting	`NCT06036836` - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)	Phase 2
Terminated	`NCT04586335` - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Phase 1
Completed	`NCT03820024` - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback	N/A
Active, not recruiting	`NCT05082025` - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations	Phase 2
Active, not recruiting	`NCT00587886` - Estrogen, Diet, Genetics and Endometrial Cancer
Completed	`NCT05378152` - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity	N/A
Suspended	`NCT05124743` - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting	`NCT03876860` - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis	N/A
Recruiting	`NCT04569773` - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed	`NCT04534309` - Behavioral Weight Loss Program for Cancer Survivors in Maryland	N/A
Not yet recruiting	`NCT05998798` - Revealing Engagement Patterns Among Endometrial Cancer Patients
Not yet recruiting	`NCT06073184` - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium	Phase 2
Not yet recruiting	`NCT06366347` - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab	Phase 2
Terminated	`NCT02907073` - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter	Phase 1/Phase 2
Completed	`NCT02413606` - ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?	N/A